Cue Biopharma, Inc.(CUE)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Cue Biopharma, Inc. (CUE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CUE at 28.9/100 on a 32-signal composite quality model, placing it at rank #2,543 of 2,962 stocks — the bottom half of the AI-ranked universe. CUE scores in the top quartile across revenue growth (97.8). Areas of concern include balance sheet strength (0.1) and profitability (3.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cue Biopharma, Inc. reports quarterly revenue of $7.9M, net income of $-153.1M, free cash flow of $-29.0M. Top institutional holders of CUE by reported 13-F value include Bleichroeder, DRIEHAUS CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CUE trades on the Nasdaq exchange and files with the SEC under CIK 1645460. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CUE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cue Biopharma, Inc. directly from SEC EDGAR.